Ranbaxy to manufacture and market Fenofibrate Capsules USP 43 mg and 130 mg

Last Updated : Nov 05 2014 | 9:38 PM IST

After USFDA approval

Ranbaxy Laboratories announced that the Company has received approval from the USFDA to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg.

Powered by Capital Market - Live News

Connect with us on WhatsApp

Ranbaxy posts Q2 profit

Ranbaxy posts loss on provision for U.S. settlement

Ranbaxy Laboratories posts loss in June quarter

Ranbaxy posts March-quarter loss on write-offs

Ranbaxy posts loss after write-offs on US import bans

First Published: Nov 05 2014 | 4:05 PM IST

Explore News

Market LIVE
Parliament Winter Session 2024 LIVE
Latest News LIVE
Market Today
Stocks To Watch Today
Vishal Mega Mart IPO Allotment
Mobikwik IPO Allotment Today
Sai Life Sciences IPO Allotment
IPO News
Business Standard at 50